Physician profile

Rachel Bui

Dentist · Vista, CA

NPI 1598283525

$209.08

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$98.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Orapharma, A Division of Bausch Health US, LLC $47.94 2020-2021
Kerr Corporation $33.41 2020-2022
Merck Sharp & Dohme LLC $28.32 2024 Delstrigo
Viiv Healthcare Company $26.31 2024 Apretude
Theratechnologies INC. $23.96 2023 Egrifta, Trogarzo
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $20.40 2023
Vyera Pharmaceuticals, LLC $16.69 2022
Dentsply Sirona INC $12.05 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rachel Bui

$209.08

in general payments reported 2019-2025

Years
2020-2024
Top company
Orapharma, A Division of Bausch Health US, LLC

https://glasscript.com/doctor/3615596/rachel-bui

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.